Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (261-270 of 386) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trialMichael A Carducci, Robert J Padley, Jurgen Breul, et al.
Leukemia|June 11, 2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasK W Pratz, E Cho, M J Levis, et al.
British Journal of Cancer|February 22, 2017
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trialRoberto Pili, Glenn Liu, Sreenivasulu Chintala, et al.
The Oncologist|January 24, 2013
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Elisabeth I Heath, David C Smith, et al.
European Urology Oncology|December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant ChemotherapyPetros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
The Oncologist|August 9, 2023
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399Ryan D Gentzler, Liza C Villaruz, John C Rhee, et al.
The Oncologist|July 7, 2016
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With SunitinibDaniel Keizman, David Sarid, Jae L Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.
Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.
Investigational New Drugs|May 23, 2012
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancerNilofer Azad, Arvind Dasari, John Arcaroli, et al.
Pageof 39

Showing results (261-270 of 386) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trialMichael A Carducci, Robert J Padley, Jurgen Breul, et al.
Leukemia|June 11, 2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasK W Pratz, E Cho, M J Levis, et al.
British Journal of Cancer|February 22, 2017
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trialRoberto Pili, Glenn Liu, Sreenivasulu Chintala, et al.
The Oncologist|January 24, 2013
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Elisabeth I Heath, David C Smith, et al.
European Urology Oncology|December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant ChemotherapyPetros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
The Oncologist|August 9, 2023
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399Ryan D Gentzler, Liza C Villaruz, John C Rhee, et al.
The Oncologist|July 7, 2016
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With SunitinibDaniel Keizman, David Sarid, Jae L Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.
Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.
Investigational New Drugs|May 23, 2012
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancerNilofer Azad, Arvind Dasari, John Arcaroli, et al.
Pageof 39